Objective: Female urethral stricture (FUS) is an underreported relatively rare condition, often resulting from a variety of causes. They can result from any process that causes injury to urethral epithelium which can then lead to scarring during the healing process of the injury and subsequent formation of a stricture. We report our experience with urethroplasty in women with urethral stricture with dorsal onlay BMG Urethroplasty which is considered a promising technique in view of anatomical and functional advantages. Design: Retrospective study Setting: Single-centre study conducted at Kanti Devi Medical College and Research Centre, Mathura, Uttar Pradesh, India. Population or Sample: 30 female patients diagnosed with urethral stricture who underwent dorsal onlay BMG urethroplasty between February 2017 and February 2024. Methods: The study involved 30 female patients diagnosed with urethral stricture. Diagnostic methods included patient symptoms, post-void residual urine measurements, uroflowmetry, MCUG, and cystoscopy. The surgical techniques was dorsal onlay BMG Urethroplasty. The indication was those female patients with urethral stricture having failed urethral dilatation more than once. The patients were followed postoperatively at 3, 6, and 12 months and annually for up to five years. Key outcomes were improvement in LUTS, Qmax, post-void residual (PVR) urine, and stricture recurrence. Main Outcome Measures: Improvement in Qmax, PVR urine volume, and stricture recurrence rate. Results: The mean age of the patients was 50.77 ± 6.14 years. Preoperative uroflowmetry showed a mean Qmax of 7.05 ± 1.81 mL/s, which improved significantly to 19.5 ± 2.83 mL/s postoperatively (p < 0.0001). Mean preoperative PVR was 116.07 ± 21.99 mL, which decreased to 29.13 ± 13.09 mL postoperatively (p < 0.0001). The success rate of the procedure was 90%, with a recurrence rate of 10%, managed with self-urethral dilation. No patient developed de novo urinary incontinence. Conclusions: Dorsal onlay BMG urethroplasty is a safe, effective, and technically feasible treatment for FUSD, demonstrating a high success rate and minimal risk of complications.